Logo do repositório
 
Publicação

Statement on combined hormonal contraceptives containing third or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

2013Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorBitzer, Johannes
dc.contributor.authorAmy, Jean-Jacques
dc.contributor.authorBeerthuizen, Rob
dc.contributor.authorBirkhäuser, Martin
dc.contributor.authorBombas, Teresa
dc.contributor.authorCreinin, Mitchell
dc.contributor.authorDarney, Philip D
dc.contributor.authorVicente, Lisa Ferreira
dc.date.accessioned2015-10-13T15:23:37Z
dc.date.available2015-10-13T15:23:37Z
dc.date.issued2013
dc.description.abstractThe controversy around the combined hormonal contraceptives (CHCs) of the so-called third (containing gestodene or desogestrel) and fourth generation (containing drospirenone, DRSP) has reached a highly emotional political dimension in which all those who are professionally responsible for women’s health are involved: the national health authorities, the pharmaceutical companies, the professional organisations, the prescribers, the media and the public (i.e. the current or potential users of CHCs). The – initially scientific – controversy has now led to a public health dispute that culminated in the decision of the French authorities to withdraw the combination containing ethinylestradiol (EE) and cyproterone acetate (CPA) from the market. The potential impact of this measure, namely the loss of confidence in all CHCs, could be quite serious.pt_PT
dc.identifier.doidoi:10.1136/jfprhc-2013-100624
dc.identifier.urihttp://hdl.handle.net/10400.26/9916
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBMJpt_PT
dc.relation.publisherversionhttp://jfprhc.bmj.com/content/39/3/156.full?sid=0c636c54-4a4e-410b-8451-278587553f24pt_PT
dc.subjectSaúde Sexual e Reprodutivapt_PT
dc.subjectContracetivos Hormonaispt_PT
dc.subjectTromboembolismopt_PT
dc.subjectProgestogéniopt_PT
dc.titleStatement on combined hormonal contraceptives containing third or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolismpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleJournal of Family Planning and Reproductive Health Carept_PT
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Statement_on_combined_hormonal_contracetives.pdf
Tamanho:
92.69 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.85 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

CI - DGS - Artigos Científicos